WHO ICTRP trial
EUCTR2008-001966-10-HU · Merck Serono SA - Geneva
EUCTR2008-001966-10-HU · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-001966-10-HU |
|---|---|
| Scientific title | A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinson’s disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving… |
| Primary sponsor | Merck Serono SA - Geneva |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Hungary;United Kingdom;Estonia;Austria |
| Conditions | Idiopathic Parkinson's Disease MedDRA version: 9.1 Level: LLT Classification code 10061536 Term: Parkinson's disease |
| Interventions | Product Name: Safinamide Product Code: NW-1015 Pharmaceutical Form: Coated tablet INN or Proposed INN: Safinamide CAS Number: 202825-46-5 Current Sponsor code: NW-1015 Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Jun 4, 2009 |
| Target size | 416 |
| Secondary IDs | 27937 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: